Sara Mccoy, MD PhD

Dr. Sara McCoy is an Assistant Professor in Rheumatology and the Director of the University of Wisconsin Health Sjögren Clinic. Her goal is to critically inform the pathogenesis of Sjögren’s disease toward development of novel targeted therapeutics. Her bench research focuses on the immunobiology of mesenchymal stromal cells derived from salivary glands and discovery of novel Sjögren’s disease autoantibodies. Her translational work deploys mesenchymal stromal cells to treat dry mouth. She is a board member of the Sjögren’s Foundation. Additionally, Dr. McCoy is a co-chair for the Sjögren’s OMERACT working group, that works to develop clinical trials endpoints in Sjögren disease and also leads the national Sjögren’s provider collaboration network-“Sjo-Net”.
Financial relationships
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:AmgenTopic:sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:NovartisTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:vor bioTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:J&JTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:ArgenxTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:Executive roleIneligible company:Quench TherapeuticsTopic:radiation xerostomiaDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:Executive roleIneligible company:OtsukaTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:ArtivaTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:VeloxisTopic:Sjogren'sDate added:07/17/2026Date updated:07/17/2026

Facebook
X
LinkedIn
Forward